New immune cell therapy aims to stop deadly leukemia return
NCT ID NCT05015426
Summary
This early-stage trial tests whether infusing specially prepared immune cells from a transplant donor can prevent acute myeloid leukemia from returning in high-risk patients. Researchers will determine the safest dose and see if this approach improves survival without causing harmful side effects. The study involves 20 adults who have recently received a stem cell transplant but remain at high risk of their cancer coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.